financetom
Business
financetom
/
Business
/
No immediate relief for Amazon, Flipkart against CCI probe
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
No immediate relief for Amazon, Flipkart against CCI probe
Jun 17, 2021 2:38 AM

Not giving immediate relief to e-commerce giants Flipkart and Amazon, a Karnataka high court division bench on Friday posted their appeals against a probe by the Competition Commission of India (CCI) for a full hearing and the matter will be heard on Monday. The companies are seeking a stay on the court's order allowing a probe by the competition watchdog against them for alleged anti-competitive practices.

Share Market Live

NSE

Earlier, Amazon and Flipkart had filed a writ appeal against the court's order last week dismissing the petitions by the companies that sought to quash a probe by the CCI against them over alleged competitive practices. The matter is likely to be heard on Friday.

Karnataka high court on June 11 dismissed the petitions by the e-commerce players, over a year-and-a-half after giving the companies an interim stay on the CCI probe.

The competition watchdog had, on January 13 2020, ordered a probe against Amazon, Flipkart on alleged anti-competitive practices on a case filed by the Delhi Vyaar Mahasangh under Section 3 of the Competition Act.

Section 3 of the Act deals with anti-competitive agreements, and the Delhi-based association had alleged that both Amazon and Flipkart were indulging in exclusive arrangements with smartphone makers, preferential treatment to some sellers, and deep discounting.

The CCI had said there was a prima facie case and had asked the director-general to investigate both the companies. The Karnataka High Court had in February last year granted an interim stay on the CCI order after both companies approached it.

The Competition Commission of India (CCI) had defended its move to order a probe against Amazon and Flipkart over anti-trust behaviour, which includes allegations of exclusive agreements with smartphone makers, stating that such agreements are often ‘tacit’.

First Published:Jun 17, 2021 11:38 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
COPT Defense Acquires 142,000 Square Foot Building in Chantilly, VA
COPT Defense Acquires 142,000 Square Foot Building in Chantilly, VA
Oct 30, 2025
COLUMBIA, Md.--(BUSINESS WIRE)-- COPT Defense Properties ( CDP ) (“COPT Defense” or the “Company”) announced the acquisition of Stonegate I, a 142,000 square foot Class A office building at 15050 Conference Center Drive in Chantilly, VA for a gross purchase price of $40.2 million. The Class A office building is fully occupied by a top 20 U.S. Defense Contractor with...
Standex Q1 sales beat expectations on new product launches
Standex Q1 sales beat expectations on new product launches
Oct 30, 2025
Overview * Standex ( SXI ) fiscal Q1 sales rise 27.6% yr/yr, beating analyst expectations, per LSEG data * Adjusted EPS for fiscal Q1 beats consensus, reflecting pricing and productivity actions * Company paid down ~$8 mln of debt, lowering net debt to EBITDA ratio to 2.4x Outlook * Standex ( SXI ) raises FY26 sales outlook to over $110...
Coinbase Global Q3 Adjusted Earnings, Revenue Rises
Coinbase Global Q3 Adjusted Earnings, Revenue Rises
Oct 30, 2025
04:14 PM EDT, 10/30/2025 (MT Newswires) -- Coinbase Global ( COIN ) reported Q3 adjusted earnings late Thursday of $1.44 per diluted share, up from $0.63 a year earlier. Analysts surveyed by FactSet expected $1.32. Revenue in the three months ended Sept. 30 rose to $1.87 billion from $1.20 billion a year earlier. Analysts polled by FactSet expected $1.80 billion....
Genomics company Illumina Q3 revenue beats expectations, helped by clinical market growth
Genomics company Illumina Q3 revenue beats expectations, helped by clinical market growth
Oct 30, 2025
Overview * Illumina ( ILMN ) Q3 revenue of $1.08 bln beats analyst expectations * Adjusted EPS of $1.34 for Q3 beats consensus estimates * Company repurchased 1.2 mln shares for $120 mln Outlook * Company expects FY25 constant currency revenue decline of (1.5%) to (0.5%) * Illumina ( ILMN ) raises FY25 non-GAAP EPS guidance to $4.65 - $4.75...
Copyright 2023-2026 - www.financetom.com All Rights Reserved